SHANGHAI, China, March 21 /Xinhua-PRNewswire/ -- WuXi PharmaTech announced today that its new animal facility has been approved by The Shanghai Administration Office of Laboratory Animal. This represents an important strategic expansion of PharmaTech's interest in the biological service sector.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
Located in the company's research campus in WaiGaoQiao Free Trade Zone in Shanghai, the 3,300 sq. ft. fully GLP compliant animal facility features individually ventilated cages (IVC) in a double barrier environment. With the establishment of the animal facility, WuXi PharmaTech can now provide a full range of biological assays including toxicology, pharmacokinetic and bioscreening, in addition to WuXi PharmaTech's current chemistry, bioanalytical and manufacturing capabilities.
"I am very pleased that our animal facility has passed the regulatory approval. There is much demand in the service biology area. Biological assays compliment our current chemistry capabilities and can bring more value to our partners," commented Angela Wong, the newly appointed vice president of service biology.
About WuXi PharmaTech
Founded in 2001, the Shanghai-based WuXi PharmaTech Co., Ltd., is the leader in the pharmaceutical R&D services industry in China. WuXi PharmaTech assists global pharmaceutical and biopharmaceutical companies in shortening the cycle and lowering the cost of drug research and development, and helps clients fully leverage the lower cost R&D capacity in China.
As an integrated drug R&D outsourcing service company, WuXi PharmaTech provides discovery and development services to our partners from lead identification to pre-clinical through our state-of-the-art facilities. The company has a broad service spectrum ranging from lead generation and optimization, in vivo and in vitro ADMET profiling, bioanalytical services, to chemistry process development and large scale manufacturing. There are over 750 scientific staff members and its management team consists of veterans from U.S., India and Japan pharmaceutical industry. WuXi PharmaTech has a 360,000 sq. ft. state-of-the-art research center in WaiGaoQiao Free Trade Zone and a 250,000 sq. ft. and ISO 9001:2000 certified GMP plant in Jinshan Chemical Industry Development Zone, Shanghai. The company's customers include 19 of the top 20 pharmaceutical companies and 8 of the top 10 biopharmaceutical companies in the world.
For more information, please contact: David Yin Public Relations WuXi PharmaTech Tel: +86-21-5046-4003 Email: yin_xiaojun@pharmatechs.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, +1-888-776-6555 or +1-212-782-2840WuXi PharmaTech Co., Ltd.CONTACT: David Yin, Public Relations of WuXi PharmaTech, +86-21-5046-4003,or yin_xiaojun@pharmatechs.com
